These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 22703625

  • 21. LDL species heterogeneity in the atherogenic dyslipidemia of polycystic ovary syndrome.
    Doi SA, Abbas JM, Parkinson L, Chakraborty J, Akanji AO.
    Am J Clin Pathol; 2008 May; 129(5):802-10. PubMed ID: 18426742
    [Abstract] [Full Text] [Related]

  • 22. Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents.
    Glueck CJ, Morrison JA, Friedman LA, Goldenberg N, Stroop DM, Wang P.
    Metabolism; 2006 Apr; 55(4):508-14. PubMed ID: 16546482
    [Abstract] [Full Text] [Related]

  • 23. Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.
    Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman Sel-D.
    J Diabetes Complications; 2010 Apr; 24(5):325-33. PubMed ID: 19553142
    [Abstract] [Full Text] [Related]

  • 24. The different phenotypes of polycystic ovary syndrome: no advantages for identifying women with aggravated insulin resistance or impaired lipids.
    Cupisti S, Haeberle L, Schell C, Richter H, Schulze C, Hildebrandt T, Oppelt PG, Beckmann MW, Dittrich R, Mueller A.
    Exp Clin Endocrinol Diabetes; 2011 Sep; 119(8):502-8. PubMed ID: 21553368
    [Abstract] [Full Text] [Related]

  • 25. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.
    Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS.
    J Clin Endocrinol Metab; 2008 Feb; 93(2):470-6. PubMed ID: 18056772
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Serum HLA-G levels in women with polycystic ovary syndrome.
    Oztekin O, Fenkci SM, Fenkci V, Enli Y, Cabus U.
    Gynecol Endocrinol; 2015 Mar; 31(3):243-6. PubMed ID: 25403326
    [Abstract] [Full Text] [Related]

  • 29. Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia.
    Uzun H, Benian A, Madazli R, Topçuoğlu MA, Aydin S, Albayrak M.
    Gynecol Obstet Invest; 2005 Mar; 60(4):195-200. PubMed ID: 16088195
    [Abstract] [Full Text] [Related]

  • 30. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women.
    Maitra A, Pingle RR, Menon PS, Naik V, Gokral JS, Meherji PK.
    Int J Fertil Womens Med; 2001 Mar; 46(5):271-7. PubMed ID: 11720200
    [Abstract] [Full Text] [Related]

  • 31. Serum resistin and adiponectin levels in women with polycystic ovary syndrome.
    Yilmaz M, Bukan N, Demirci H, Oztürk C, Kan E, Ayvaz G, Arslan M.
    Gynecol Endocrinol; 2009 Apr; 25(4):246-52. PubMed ID: 19408174
    [Abstract] [Full Text] [Related]

  • 32. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors.
    Rocha MP, Marcondes JA, Barcellos CR, Hayashida SA, Curi DD, da Fonseca ÂM, Bagnoli VR, Baracat EC.
    Gynecol Endocrinol; 2011 Oct; 27(10):814-9. PubMed ID: 20807166
    [Abstract] [Full Text] [Related]

  • 33. Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
    Kilicdag EB, Bagis T, Zeyneloglu HB, Tarim E, Aslan E, Haydardedeoglu B, Erkanli S.
    Hum Reprod; 2005 Apr; 20(4):894-9. PubMed ID: 15618250
    [Abstract] [Full Text] [Related]

  • 34. Retinol-binding protein in nonobese women with polycystic ovary syndrome.
    Lee JW, Im JA, Lee DC, Lee HR, Shim JY.
    Clin Endocrinol (Oxf); 2008 May; 68(5):786-90. PubMed ID: 17986278
    [Abstract] [Full Text] [Related]

  • 35. Antioxidant properties of high-density lipoproteins are impaired in women with polycystic ovary syndrome.
    Zhang J, Zhang Y, Liu H, Bai H, Wang Y, Jiang C, Fan P.
    Fertil Steril; 2015 May; 103(5):1346-54. PubMed ID: 25813288
    [Abstract] [Full Text] [Related]

  • 36. Dyslipidemia and oxidative stress in PCOS.
    Macut D, Bjekić-Macut J, Savić-Radojević A.
    Front Horm Res; 2013 May; 40():51-63. PubMed ID: 24002405
    [Abstract] [Full Text] [Related]

  • 37. Oxidative stress markers in young patients with polycystic ovary syndrome, the relationship between insulin resistances.
    Karadeniz M, Erdoğan M, Tamsel S, Zengi A, Alper GE, Cağlayan O, Saygili F, Yilmaz C.
    Exp Clin Endocrinol Diabetes; 2008 Apr; 116(4):231-5. PubMed ID: 18393129
    [Abstract] [Full Text] [Related]

  • 38. Apolipoprotein E-containing HDL-associated platelet-activating factor acetylhydrolase activities and malondialdehyde concentrations in patients with PCOS.
    Fan P, Liu H, Wang Y, Zhang F, Bai H.
    Reprod Biomed Online; 2012 Feb; 24(2):197-205. PubMed ID: 22197603
    [Abstract] [Full Text] [Related]

  • 39. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA, Shin SY, Yoon BK, Choi D.
    Gynecol Endocrinol; 2007 Feb; 23(8):461-7. PubMed ID: 17852414
    [Abstract] [Full Text] [Related]

  • 40. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease.
    Atamer A, Kocyigit Y, Ecder SA, Selek S, Ilhan N, Ecder T, Atamer Y.
    J Nephrol; 2008 Feb; 21(6):924-30. PubMed ID: 19034878
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.